Cargando…

Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments

PURPOSE: To elucidate and compare benefit–risk preferences among Korean patients and physicians concerning cyclooxygenase-2 (Cox-2) inhibitor treatments for arthritis. MATERIALS AND METHODS: Subjects included 100 patients with arthritis and 60 board-certified orthopedic surgeon physicians in South K...

Descripción completa

Detalles Bibliográficos
Autores principales: Byun, Ji-Hye, Kwon, Sun-Hong, Lee, Ji-Eun, Cheon, Ji-Eun, Jang, Eun-Jin, Lee, Eui-Kyung
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854248/
https://www.ncbi.nlm.nih.gov/pubmed/27175064
http://dx.doi.org/10.2147/PPA.S98228
_version_ 1782430198925361152
author Byun, Ji-Hye
Kwon, Sun-Hong
Lee, Ji-Eun
Cheon, Ji-Eun
Jang, Eun-Jin
Lee, Eui-Kyung
author_facet Byun, Ji-Hye
Kwon, Sun-Hong
Lee, Ji-Eun
Cheon, Ji-Eun
Jang, Eun-Jin
Lee, Eui-Kyung
author_sort Byun, Ji-Hye
collection PubMed
description PURPOSE: To elucidate and compare benefit–risk preferences among Korean patients and physicians concerning cyclooxygenase-2 (Cox-2) inhibitor treatments for arthritis. MATERIALS AND METHODS: Subjects included 100 patients with arthritis and 60 board-certified orthopedic surgeon physicians in South Korea. Through a systematic review of the literature, beneficial attributes of using Cox-2 inhibitors were defined as a decrease in the Western Ontario and McMaster Universities Arthritis Index for pain score and improvement in physical function. Likewise, risk attributes included upper gastrointestinal (GI) complications and cardiovascular (CV) adverse events. Discrete choice experiments were used to determine preferences for these four attributes among Korean patients and physicians. Relative importance and maximum acceptable risk for improving beneficial attributes were assessed by analyzing the results of the discrete choice experiment by using a conditional logit model. RESULTS: Patients ranked the relative importance of benefit–risk attributes as follows: pain reduction (35.2%); physical function improvement (30.0%); fewer CV adverse events (21.5%); fewer GI complications (13.4%). The physicians’ ranking for the same attributes was as follows: fewer CV (33.5%); pain reduction (32.4%); fewer GI complications (18.1%); physical function improvement (16.0%). Patients were more willing than physicians to accept risks when pain improved from 20% or 45% to 55% and physical function improved from 15% or 35% to 45%. CONCLUSION: We confirmed that patients and physicians had different benefit–risk preferences regarding Cox-2 inhibitors. Patients with arthritis prioritized the benefits of Cox-2 inhibitors over the risks; moreover, in comparison with the physicians, arthritis patients were more willing to accept the trade-off between benefits and risks to achieve the best treatment level. To reduce the preference gap and achieve treatment goals, physicians must better understand their patients’ preferences.
format Online
Article
Text
id pubmed-4854248
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48542482016-05-12 Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments Byun, Ji-Hye Kwon, Sun-Hong Lee, Ji-Eun Cheon, Ji-Eun Jang, Eun-Jin Lee, Eui-Kyung Patient Prefer Adherence Original Research PURPOSE: To elucidate and compare benefit–risk preferences among Korean patients and physicians concerning cyclooxygenase-2 (Cox-2) inhibitor treatments for arthritis. MATERIALS AND METHODS: Subjects included 100 patients with arthritis and 60 board-certified orthopedic surgeon physicians in South Korea. Through a systematic review of the literature, beneficial attributes of using Cox-2 inhibitors were defined as a decrease in the Western Ontario and McMaster Universities Arthritis Index for pain score and improvement in physical function. Likewise, risk attributes included upper gastrointestinal (GI) complications and cardiovascular (CV) adverse events. Discrete choice experiments were used to determine preferences for these four attributes among Korean patients and physicians. Relative importance and maximum acceptable risk for improving beneficial attributes were assessed by analyzing the results of the discrete choice experiment by using a conditional logit model. RESULTS: Patients ranked the relative importance of benefit–risk attributes as follows: pain reduction (35.2%); physical function improvement (30.0%); fewer CV adverse events (21.5%); fewer GI complications (13.4%). The physicians’ ranking for the same attributes was as follows: fewer CV (33.5%); pain reduction (32.4%); fewer GI complications (18.1%); physical function improvement (16.0%). Patients were more willing than physicians to accept risks when pain improved from 20% or 45% to 55% and physical function improved from 15% or 35% to 45%. CONCLUSION: We confirmed that patients and physicians had different benefit–risk preferences regarding Cox-2 inhibitors. Patients with arthritis prioritized the benefits of Cox-2 inhibitors over the risks; moreover, in comparison with the physicians, arthritis patients were more willing to accept the trade-off between benefits and risks to achieve the best treatment level. To reduce the preference gap and achieve treatment goals, physicians must better understand their patients’ preferences. Dove Medical Press 2016-04-26 /pmc/articles/PMC4854248/ /pubmed/27175064 http://dx.doi.org/10.2147/PPA.S98228 Text en © 2016 Byun et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Byun, Ji-Hye
Kwon, Sun-Hong
Lee, Ji-Eun
Cheon, Ji-Eun
Jang, Eun-Jin
Lee, Eui-Kyung
Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments
title Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments
title_full Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments
title_fullStr Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments
title_full_unstemmed Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments
title_short Comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments
title_sort comparison of benefit–risk preferences of patients and physicians regarding cyclooxygenase-2 inhibitors using discrete choice experiments
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4854248/
https://www.ncbi.nlm.nih.gov/pubmed/27175064
http://dx.doi.org/10.2147/PPA.S98228
work_keys_str_mv AT byunjihye comparisonofbenefitriskpreferencesofpatientsandphysiciansregardingcyclooxygenase2inhibitorsusingdiscretechoiceexperiments
AT kwonsunhong comparisonofbenefitriskpreferencesofpatientsandphysiciansregardingcyclooxygenase2inhibitorsusingdiscretechoiceexperiments
AT leejieun comparisonofbenefitriskpreferencesofpatientsandphysiciansregardingcyclooxygenase2inhibitorsusingdiscretechoiceexperiments
AT cheonjieun comparisonofbenefitriskpreferencesofpatientsandphysiciansregardingcyclooxygenase2inhibitorsusingdiscretechoiceexperiments
AT jangeunjin comparisonofbenefitriskpreferencesofpatientsandphysiciansregardingcyclooxygenase2inhibitorsusingdiscretechoiceexperiments
AT leeeuikyung comparisonofbenefitriskpreferencesofpatientsandphysiciansregardingcyclooxygenase2inhibitorsusingdiscretechoiceexperiments